DZD6008
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for DZD6008, covering 2025-08-29 to 2026-02-27. Get the full timeline:
Most recent: Clinical Trial Update: A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1) [Phase 1]